Urine-based Cancer Detection Technology Validated

              Urine-based Cancer Detection Technology Validated

Trovagene develops ultra-sensitive cell-free DNA assay

PR Newswire

SAN DIEGO, July 22, 2013

SAN DIEGO, July 22, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ: TROV)
announces that results emerging from ongoing clinical studies have confirmed
the broad applicability of Trovagene technology across a variety of cancer
types, and the successful development of a molecular diagnostic test capable
of detecting and quantifying oncogene mutations from a simple urine specimen.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

The ability to regularly detect and monitor the results of cancer treatment
through a non-invasive, systemic sample could significantly help patients who
require therapy for recurrent or metastatic cancer.

Clinical validation of Trovagene's ultra-sensitive assay procedure has been
confirmed initially for detection of the BRAF mutation from cell-free (cf) DNA
in urine.The cf-BRAF test will be available as a laboratory developed test
(LDT) this quarter, and offered through the company's CLIA lab.

"Our ability to detect and quantify oncogenic mutations in the urine of cancer
patients represents a significant step towards better patient monitoring,"
said Mark Erlander, Ph.D., chief scientific officer for Trovagene. "The
analytic performance levels required to achieve this are made possible through
the large sample volumes available from urine, combined with state-of-the-art
digital PCR and sequencing platforms."

Trovagene is developing numerous cell-free assays that target clinically
actionable oncogene mutations, including BRAF, KRAS, PIK3CA and others.Given
the recent approval of several new targeted therapies to treat BRAF-mutation
positive melanoma, Trovagene prioritized the development of the BRAF assay to
address the clinical need to monitor patient response to these therapies. BRAF
mutations are prevalent in many different cancers. Trovagene's cf-BRAF
mutation assay is being validated across a range of solid tumors, confirming
that urine-based mutation detection is applicable across many cancer types.

Building on this ability to detect single mutations, Trovagene is now
developing assay panels to broaden its cancer monitoring capabilities using
next-generation sequencing platforms. Many cancers exhibit multiple oncogenic
mutations and genomic variations, and can develop new resistance mutations
during the course of disease and treatment. Targeted cancer monitoring panels
may provide a cost-effective way of following these patients throughout their
disease as compared to current standard-of-care monitoring techniques, which
include CT and PET scans.

"Measuring the genomic changes underlying a patients' tumor can result in
clinically actionable information that benefits the patient and the treating
physician," stated Antonius Schuh, Ph.D., chief executive officer of
Trovagene. "The additional capability to non-invasively monitor a patients'
cancer in near-real time may improve the overall management of cancer, leading
to better patient outcomes."

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its patented
technology for the detection of cell-free DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that can be
isolated and detected from urine. Trovagene has a strong intellectual property
asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and
European patent applications and issued patents that cover testing for HPV and
other infectious diseases, cancer, transplantation, prenatal and genetic
testing.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or fourth party payer reimbursement; limited sales
and marketing efforts and dependence upon fourth parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2012 and other periodic reports filed with the
Securities and Exchange Commission.

Contact:

Trovagene, Inc.

Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.
858-952-7594
szaniboni@trovagene.com

SOURCE Trovagene, Inc.

Website: http://www.trovagene.com